# US 2024/0316102 A1 · Engineered natural killer (nk) cells and related methods

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0316102 A1
- Document ID: US20240316102A1
- Status: Published application
- Kind: A1
- Application number: 18/573,893
- Filed: 2022-06-30
- Published: 2024-09-26
- Earliest claimed: 2021-07-01
- Assignees: Indapta Therapeutics, Inc.
- Applicants: Indapta Therapeutics, Inc.
- Inventors: Guy DIPIERRO; Austin BIGLEY
- Web page: https://patentgrep.com/patent/US20240316102A1

## CPC

- A61K 40/15: Natural-killer [NK] cells; Natural-killer T [NKT] cells
- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A61K 35/17: Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00)
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 40/4221: {CD20}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- C07K 14/5443: {IL-15}
- C07K 14/55: IL-2
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C07K 14/70535: {Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)}
- C12N 5/0646: {Natural killers cells [NK], NKT cells}
- C12N 15/86: Viral vectors
- A61K 2039/804: {Blood cells [leukemia, lymphoma]}
- A61K 2239/13: Antibody-based
- A61K 2239/21: Transmembrane domain
- A61K 2239/48: Blood cells, e.g. leukemia or lymphoma
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2319/02: containing a signal sequence
- C07K 2319/03: containing a transmembrane segment
- C12N 2501/2302: Interleukin-2 (IL-2)
- C12N 2501/2312: Interleukin-12 (IL-12)
- C12N 2501/2315: Interleukin-15 (IL-15)
- C12N 2501/2318: Interleukin-18 (IL-18)
- C12N 2501/2321: Interleukin-21 (IL-21)
- C12N 2501/2327: Interleukin-27 (IL-27)
- C12N 2510/00: Genetically modified cells
- C12N 2740/15043: viral genome or elements thereof as genetic vector
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Provided herein are engineered Natural Killer (NK) cells deficient in expression of FcRγ chain (g-NK cells), and further comprising a recombinant chimeric antigen receptor (CAR) and compositions thereof. Also provided herein are compositions containing the engineered NK cells and methods of making and using the engineered NK cells.

## Claims

### Claim 1

An engineered Natural Killer (NK) cell that is deficient in expression of FcRγ chain (g-NK cells) and comprises a heterologous nucleic acid encoding a chimeric antigen receptor (CAR).

### Claim 2

An engineered Natural Killer (NK) cell that is deficient in expression of FcRγ chain (g-NK cells), and comprises a heterologous nucleic acid encoding an immunomodulator.

### Claim 3

An engineered Natural Killer (NK) cell that is deficient in expression of FcRγ chain (g-NK cells), and comprises a heterologous nucleic acid encoding a chimeric antigen receptor (CAR) and a heterologous nucleic acid encoding an immunomodulator.

### Claim 4 (depends on 1, 3)

The engineered NK cell of claim 1 or claim 3, wherein the CAR comprises 1) an antigen binding domain; 2) a flexible linker; 3) a transmembrane region; and 4) an intracellular signaling domain.

### Claim 5 (depends on 4)

The engineered NK cell of claim 4, wherein the antigen binding domain is targeted against a tumor antigen.

### Claim 6 (depends on 4, 5)

The engineered NK cell of claim 4 or claim 5, wherein the antigen binding domain is a single chain variable fragment (scFv).

### Claim 7 (depends on 4, 5, 6)

The engineered NK cell of any of claims 4-6, wherein the intracellular signaling domain comprises a primary signaling domain and a costimulatory signaling domain.

### Claim 8 (depends on 4, 5, 6, 7)

The engineered NK cell of any of claims 4-7, wherein the intracellular signaling domain comprises one or more signaling domains of CD3ζ, DAP10, DAP12, CD28, 4-1BB, or OX40.

### Claim 9 (depends on 4, 5, 6, 7)

The engineered NK cell of any of claims 4-7, wherein the intracellular signaling domain comprises two or more signaling domains of CD3ζ, DAP10, DAP12, CD28, 4-1BB, or OX40.

### Claim 10 (depends on 4, 5, 6, 7, 8, 9)

The engineered NK cell of any of claims 4-9, wherein the intracellular signaling domain comprises a primary signaling domain comprising a signaling domain of CD3ζ and a costimulatory signaling domain.

### Claim 11 (depends on 10)

The engineered NK cell of claim 10, wherein the costimulatory signaling domain is a signaling domain of CD28 or 4-1BB.

### Claim 12 (depends on 1, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The engineered NK cell of any of claims 1 or 3-11, wherein the heterologous nucleic acid encoding the CAR is stably integrated into the genome of the cell.

### Claim 13 (depends on 1, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The engineered NK cell of any of claims 1 or 3-11, wherein the heterologous nucleic acid encoding the CAR is transiently expressed.

### Claim 14 (depends on 2, 3)

The engineered NK cell of claim 2 or claim 3, wherein the immunomodulator is an immunosuppressant.

### Claim 15 (depends on 2, 3)

The engineered NK cell of claim 2 or claim 3, wherein the immunomodulator is an immunoactivator.

### Claim 16 (depends on 2, 3)

The engineered NK cell of any one of claims 2, 3, or 15, wherein the immunomodulator is a cytokine.

### Claim 17 (depends on 16)

The engineered NK cell of claim 16, wherein the cytokine is secretable from the engineered NK cell.

### Claim 18 (depends on 17)

The engineered NK cell of claim 17, wherein the secretable cytokine is IL-2 or a biological portion thereof; IL-15 or a biological portion thereof; or IL-21 or a biological portion thereof; or combinations thereof.

### Claim 19 (depends on 16)

The engineered NK cell of claim 16, wherein the cytokine is membrane-bound.

### Claim 20 (depends on 19)

The engineered NK cell of claim 19, wherein the membrane-bound cytokine is membrane-bound IL-2 (mbIL-2); membrane-bound IL-15 (mbIL-15); membrane-bound IL-21 (mbIL-21); or combinations thereof.

### Claim 21 (depends on 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

The engineered NK cell of any of claims 2-20, wherein the heterologous nucleic acid encoding the immunomodulator is stably integrated into the genome of the cell.

### Claim 22 (depends on 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

The engineered NK cell of any of claims 2-21, wherein the heterologous nucleic acid encoding the immunomodulator is transiently expressed.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The engineered NK cell of any one of claims 1-22, wherein the g-NK cell has a surface phenotype that is CD16pos/CD57pos/CD7dim/neg/CD161neg.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

The engineered NK cell of any of claims 1-23, wherein the g-NK cell further has a surface phenotype that is NKG2Aneg/CD161neg.

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

The engineered NK cell of any of claims 1-24, wherein the g-NK cell further is CD38neg.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

The engineered NK cell of any of claims 1-25, wherein the g-NK cell has a surface phenotype that further is CD45pos/CD3neg/CD56pos.

### Claim 27 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)

The engineered NK cell of any of claims 1-26, wherein the g-NK cells comprise CD16 158V/V (V158)

### Claim 28 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)

The engineered NK cell of any of claims 1-26, wherein the g-NK cells are CD16 158V/F.

### Claim 29 (depends on 1, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

A composition comprising a plurality of engineered g-NK cells of any of claims 1, 3-13, or 23-28.

### Claim 30 (depends on 2, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

A composition comprising a plurality of engineered g-NK cells of any of claims 2 or 14-28.

### Claim 31 (depends on 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

A composition comprising a plurality of engineered g-NK cells of any of claims 3-28.

### Claim 32 (depends on 29, 30, 31)

The composition of any one of claims 29-31, wherein greater than at or about 50% of the NK cells or total cells or greater than at or about 60% of the NK cells or total cells in the composition are g-NK cells.

### Claim 33 (depends on 29, 30, 31)

The composition of any one of claims 29-31, wherein greater than at or about 70% of the NK cells or total cells in the composition are g-NK cells.

### Claim 34 (depends on 29, 30, 31)

The composition of any one of claims 29-31, wherein greater than at or about 80% of the NK cells or total cells in the composition are g-NK cells.

### Claim 35 (depends on 29, 30, 31)

The composition of any one of claims 29-31, wherein greater than at or about 90% of the NK cells or total cells in the composition are g-NK cells.

### Claim 36 (depends on 29, 30, 31)

The composition of any one of claims 29-31, wherein greater than at or about 95% of the NK cells or total cells in the composition are g-NK cells.

### Claim 37 (depends on 29, 31, 32, 33, 34, 35, 36)

The composition of any one of claims 29 or 31-36, wherein the plurality of engineered g-NK cells comprises greater than at or about 20%, greater than at or about 30%, greater than at or about 40%, greater than at or about 50%, greater than at or about 60%, or greater than at or about 70% g-NK cells comprising a heterologous nucleic acid encoding the CAR.

### Claim 38 (depends on 29, 31, 32, 33, 34, 35, 36, 37)

The composition of any one of claims 29 or 31-37, wherein the total composition comprises greater than at or about 20%, greater than at or about 30%, greater than at or about 40%, greater than at or about 50%, greater than at or about 60%, or greater than at or about 70% g-NK cells comprising a heterologous nucleic acid encoding the CAR.

### Claim 39 (depends on 30, 31, 32, 33, 34, 35, 36)

The composition of any one of claims 30-36, wherein the plurality of engineered g-NK cells comprises greater than at or about 20%, greater than at or about 30%, greater than at or about 40%, greater than at or about 50%, greater than at or about 60%, or greater than at or about 70% g-NK cells comprising a heterologous nucleic acid encoding the immunomodulator.

### Claim 40 (depends on 30, 31, 32, 33, 34, 35, 36, 39)

The composition of any one of claims 30-36 or 39, wherein the total composition comprises greater than at or about 20%, greater than at or about 30%, greater than at or about 40%, greater than at or about 50%, greater than at or about 60%, or greater than at or about 70% g-NK cells comprising a heterologous nucleic acid encoding the immunomodulator.

### Claim 41 (depends on 31, 32, 33, 34, 35, 36)

The composition of any one of claims 31-36, wherein the plurality of engineered g-NK cells comprises greater than at or about 20%, greater than at or about 30%, greater than at or about 40%, greater than at or about 50%, greater than at or about 60%, or greater than at or about 70% g-NK cells comprising a heterologous nucleic acid encoding the CAR and a heterologous nucleic acid encoding the immunomodulator.

### Claim 42 (depends on 31, 32, 33, 34, 35, 36, 41)

The composition of any one of claims 31-36 or 41 wherein the total composition comprises greater than at or about 20%, greater than at or about 30%, greater than at or about 40%, greater than at or about 50%, greater than at or about 60%, or greater than at or about 70% g-NK cells comprising a heterologous nucleic acid encoding the CAR and the heterologous nucleic acid encoding the immunomodulator.

### Claim 43 (depends on 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)

The composition of any one of claims 29-42, wherein greater than at or about 70% of the g-NK cells are positive for perforin and greater than at or about 70% of the g-NK cells are positive for granzyme B.

### Claim 44 (depends on 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43)

The composition of any one of claims 29-43, wherein greater than at or about 80% of the g-NK cells are positive for perforin and greater than at or about 80% of the g-NK cells are positive for granzyme B.

### Claim 45 (depends on 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

The composition of any one of claims 29-44, wherein greater than at or about 90% of the g-NK cells are positive for perforin and greater than at or about 90% of the g-NK cells are positive for granzyme B.

### Claim 46 (depends on 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45)

The composition of any one of claims 29-45, wherein greater than at or about 95% of the g-NK cells are positive for perforin and greater than at or about 95% of the g-NK cells are positive for granzyme B.

### Claim 47 (depends on 43, 44, 45, 46)

The composition of any of claims 43-46, wherein:
among the cells positive for perforin, the cells express a mean level of perforin as measured by intracellular flow cytometry that is, based on mean fluorescence intensity (MFI), at least at or about two times the mean level of perforin expressed by cells that are FcRγpos; and/or
among the cells positive for granzyme B, the cells express a mean level of granzyme B as measured by intracellular flow cytometry that is, based on mean fluorescence intensity (MFI), at least at or about two times the mean level of granzyme B expressed by cells that are FcRγpos.

### Claim 48 (depends on 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47)

The composition of any of claims 29-47, wherein greater than 10% of the cells in the composition are capable of degranulation against tumor target cells, optionally as measured by CD107a expression, optionally wherein the degranulation is measured in the absence of an antibody against the tumor target cells.

### Claim 49 (depends on 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48)

The composition of any of claims 29-48, wherein greater than 10% of the cells in the composition are capable of producing interferon-gamma or TNF-alpha against tumor target cells, optionally wherein the interferon-gamma or TNF-alpha is measured in the absence of an antibody against the tumor target cells.

### Claim 50 (depends on 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49)

The composition of any of claims 29-49, wherein, among the cells in the composition, greater than at or about 15%, greater than at or about 20%, greater than at or about 30%, greater than at or about 40% or greater than at or about 50% produce an effector cytokine in the presence of cells expressing a target antigen (target cells) and an antibody directed against the target antigen (anti-target antibody).

### Claim 51 (depends on 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50)

The composition of any of claims 29-50, wherein, among the total cells in the composition or among the g-NK cells in the composition, greater than at or about 30% are positive for NKG2C (NKG2Cpos) and/or greater than at or about 50% are negative or low for NKG2A (NKG2Aneg).

### Claim 52 (depends on 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51)

The composition of any of claims 29-51, wherein, among the total cells in the composition or among the g-NK cells in the composition, greater than at or about 35% are positive for NKG2C (NKG2Cpos) and/or greater than at or about 60% are negative or low for NKG2A (NKG2Aneg).

### Claim 53 (depends on 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52)

The composition of any of claims 29-52, wherein, among the total cells in the composition or among the g-NK cells in the composition, greater than at or about 40% are positive for NKG2C (NKG2Cpos) and/or greater than at or about 70% are negative or low for NKG2A (NKG2Aneg).

### Claim 54 (depends on 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52)

The composition of any of claims 29-52, wherein, among the total cells in the composition or among the g-NK cells in the composition, greater than at or about 45% are positive for NKG2C (NKG2Cpos) and/or greater than at or about 80% are negative or low for NKG2A (NKG2Aneg).

### Claim 55 (depends on 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52)

The composition of any of claims 29-52, wherein, among the total cells in the composition or among the g-NK cells in the composition, greater than at or about 50% are positive for NKG2C (NKG2Cpos) and/or greater than at or about 85% are negative or low for NKG2A (NKG2Aneg).

### Claim 56 (depends on 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52)

The composition of any of claims 29-52, wherein, among the total cells in the composition or among the g-NK cells in the composition, greater than at or about 55% are positive for NKG2C (NKG2Cpos) and/or greater than at or about 90% are negative or low for NKG2A (NKG2Aneg).

### Claim 57 (depends on 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52)

The composition of any of claims 29-52, wherein, among the total cells in the composition, or among the g-NK cells in the composition, greater than at or about 60% are positive for NKG2C (NKG2Cpos) and/or greater than at or about 95% are negative or low for NKG2A (NKG2Aneg).

### Claim 58 (depends on 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57)

The composition of any of claims 29-57, wherein, among the total cells in the composition or among the g-NK cells in the composition, greater than at or about 50%, greater than at or about 60%, greater than at or about 70%, greater than at or about 80%, or greater than at or about 90% are CD3809.

### Claim 59 (depends on 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57)

The composition of any of claims 29-57, wherein, among the total cells in the composition or among the g-NK cells in the composition, greater than at or about 50%, greater than at or about 60%, greater than at or about 70%, greater than at or about 80%, or greater than at or about 90% are CD16pos/CD57pos/CD7dim/neg/CD161neg.

### Claim 60 (depends on 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57)

The composition of any of claims 29-57, wherein, among the total cells in the composition or among the g-NK cells in the composition, greater than at or about 50%, greater than at or about 60%, greater than at or about 70%, greater than at or about 80%, or greater than at or about 90% are NKG2Aneg/CD161neg.

### Claim 61 (depends on 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60)

The composition of any of claims 29-60, wherein the plurality of g-NK cells are CD16 158V/V (V158).

### Claim 62 (depends on 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60)

The composition of any of claims 29-60, wherein the plurality of g-NK cells are CD16 158V/F.

### Claim 63 (depends on 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62)

The composition of any of claims 29-62, wherein the composition comprises at least or about at least 108 cells.

### Claim 64 (depends on 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63)

The composition of any of claims 29-63, wherein the number of g-NK cells in the composition is from at or about 108 to at or about 1012 cells, from at or about 108 to at or about 1011 cells, from at or about 108 to at or about 1010 cells, from at or about 108 to at or about 109 cells, from at or about 109 cells to at or about 1012 cells, from at or about 109 to at or about 1011 cells, from at or about 109 to at or about 1010 cells, from at or about 1010 to at or about 1012 cells, from at or about 1010 to at or about 1011 cells, or from at or about 1011 to at or about 1012 cells.

### Claim 65 (depends on 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64)

The composition of any of claims 29-64, wherein the number of g-NK cells in the composition is or is about 5×108 cells, is or is about 1×109 cells, is or is about 5×1010 cells, or is or is about 1×1010 cells.

### Claim 66 (depends on 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65)

The composition of any of claims 29-65, wherein the volume of the composition is between at or about 50 mL and at or about 500 mL, optionally at or about 200 mL.

### Claim 67 (depends on 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66)

The composition of any of claims 29-66, wherein the cells in the composition are from a single donor subject that have been expanded from the same biological sample.

### Claim 68 (depends on 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67)

The composition of any of claims 29-67, wherein the composition is a pharmaceutical composition.

### Claim 69 (depends on 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68)

The composition of any of claims 29-68, comprising a pharmaceutically acceptable excipient.

### Claim 70 (depends on 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69)

The composition of any of claims 29-69, wherein the composition is formulated in a serum-free cryopreservation medium comprising a cryoprotectant.

### Claim 71 (depends on 70)

The composition of claim 70, wherein the cryoprotectant is DMSO and the cryopreservation medium is 5% to 10% DMSO (v/v).

### Claim 72 (depends on 71)

The composition of claim 71, wherein the cryoprotectant is or is about 10% DMSO (v/v).

### Claim 73 (depends on 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72)

The composition of any of claims 29-72 that is sterile.

### Claim 74 (depends on 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73)

A sterile bag, comprising the composition of any of claims 29-73.

### Claim 75 (depends on 74)

The sterile bag of claim 74, wherein the bag is a cryopreservation-compatible bag.

### Claim 76

A method of producing a genetically engineered g-NK cell, comprising introducing into an NK cell deficient in expression of FcRγ chain (g-NK cells) a heterologous nucleic acid encoding a chimeric antigen receptor (CAR).

### Claim 77

A method of producing a genetically engineered g-NK cell, comprising introducing into the g-NK cell a heterologous nucleic acid encoding an immunomodulator, thereby producing a genetically engineered g-NK cell.

### Claim 78

A method of producing a genetically engineered g-NK cell, comprising:
(a) introducing into an NK cell deficient in expression of FcRγ chain (g-NK cells) a heterologous nucleic acid encoding a chimeric antigen receptor (CAR), and
(b) introducing into the g-NK cell a heterologous nucleic acid encoding an immunomodulator,
thereby producing a genetically engineered g-NK cell, wherein steps (a) and (b) are carried out simultaneously or sequentially in any order.

### Claim 79 (depends on 76, 78)

The method of claim 76 or claim 78, wherein the CAR comprises 1) an antigen binding domain; 2) a flexible linker (spacer); 3) a transmembrane region; and 4) an intracellular signaling domain.

### Claim 80 (depends on 79)

The method of claim 79, wherein the antigen binding domain is targeted against a tumor antigen.

### Claim 81 (depends on 79, 80)

The method of claim 79 or 80, wherein the antigen binding domain is a single chain variable fragment (scFv).

### Claim 82 (depends on 79, 80, 81)

The method of any of claims 79-81, wherein the intracellular signaling domain comprises one or more signaling domain from CD3ζ, DAP10, DAP12, CD28, 4-1BB, or OX40.

### Claim 83 (depends on 79, 80, 81, 82)

The method of any of claims 79-82, wherein the intracellular signaling domain comprises two or more signaling domains from CD3ζ, DAP10, DAP12, CD28, 4-1BB, or OX40.

### Claim 84 (depends on 79, 80, 81, 82, 83)

The method of any of claims 79-83, wherein the intracellular signaling domain comprises a primary signaling domain comprising a signaling domain of CD3ζ and a costimulatory signaling domain.

### Claim 85 (depends on 84)

The method of claim 84, wherein the costimulatory signaling domain is a signaling domain of CD28 or 4-1BB.

### Claim 86 (depends on 76, 78, 79, 80, 81, 82, 83, 84, 85)

The method of any of claims 76 or 78-85, wherein the heterologous nucleic acid encoding the CAR is introduced under conditions for stable integration into the genome of the g-NK cell.

### Claim 87 (depends on 76, 78, 79, 80, 81, 82, 83, 84, 85, 86)

The method of any of claims 76 or 78-86, wherein the heterologous nucleic acid encoding the CAR is comprised in a viral vector and is introduced into the g-NK cell by transduction.

### Claim 88 (depends on 87)

The method of claim 87, wherein the viral vector is a lentiviral vector.

### Claim 89 (depends on 76, 78, 79, 80, 81, 82, 83, 84, 85)

The method of any one of claims 76 or 78-85, wherein the nucleic acid encoding the CAR is introduced under conditions for transient expression in the g-NK cell.

### Claim 90 (depends on 76, 78, 79, 80, 81, 82, 83, 84, 85)

The method of any one of claims 76, 78-85, or 89, wherein the nucleic acid encoding the CAR is introduced by non-viral delivery.

### Claim 91 (depends on 76, 78, 79, 80, 81, 82, 83, 84, 85)

The method of any of claims 76, 78-85, or 89-90, wherein the nucleic acid encoding the CAR is introduced to the g-NK cell via a lipid nanoparticle.

### Claim 92 (depends on 76, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91)

The method of any of claims 76 or 78-91, wherein the nucleic acid encoding the CAR is DNA.

### Claim 93 (depends on 76, 78, 79, 80, 81, 82, 83, 84, 85)

The method of any of claims 76, 78-85, or 89-91, wherein the nucleic acid encoding the CAR is RNA.

### Claim 94 (depends on 93)

The method of claim 93, wherein the RNA is mRNA.

### Claim 95 (depends on 94)

The method of claim 94, wherein the RNA is a self-amplifying mRNA.

### Claim 96 (depends on 76, 78, 79, 80, 81, 82, 83, 84, 85)

The method of any of claims 76, 78-85, or 89-95, wherein the nucleic acid is introduced to the g-NK cell via electroporation.

### Claim 97 (depends on 77, 78)

The method of claim 77 or claim 78, wherein the immunomodulator is an immunosuppressant.

### Claim 98 (depends on 77, 78)

The method of any one of claim 77 or claim 78 wherein the immunomodulator is an immunoactivator.

### Claim 99 (depends on 77, 78, 98)

The method of claim 77, 78, or claim 98, wherein the immunomodulator is a cytokine.

### Claim 100 (depends on 99)

The method of claim 99, wherein the cytokine is secretable from the engineered NK cell.

### Claim 101 (depends on 100)

The method of claim 100, wherein the secretable cytokine is IL-2 or a biologically active portion thereof; IL-15 or a biologically active portion thereof; IL-21 or a biologically active portion thereof or combinations thereof.

### Claim 102 (depends on 99)

The method of claim 99, wherein the cytokine is membrane bound.

### Claim 103 (depends on 102)

The method of claim 102, wherein the membrane-bound cytokine is membrane bound IL-2 (mbIL-2); membrane-bound IL-15 (mbIL-15); or membrane bound IL-21 (mbIL-21) or combinations thereof.

### Claim 104 (depends on 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103)

The method of any one of claims 77-103, wherein the nucleic acid encoding the immunomodulator is introduced under conditions for stable integration into the genome of the g-NK cell.

### Claim 105 (depends on 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104)

The method of any of claims 77-104, wherein the nucleic acid encoding an immunomodulator is comprised in a viral vector and is introduced into the g-NK cell by transduction.

### Claim 106 (depends on 105)

The method of claim 105, wherein the viral vector is a lentiviral vector.

### Claim 107 (depends on 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103)

The method of any one of claims 77-103, wherein the nucleic acid encoding the immunomodulator is introduced under conditions for transient expression in the g-NK cell.

### Claim 108 (depends on 77, 78, 79, 80, 81, 82, 83, 84, 85, 89, 90)

The method of any one of claims 77-85, 89-90, or 97-107, wherein the nucleic acid encoding the immunomodulator is introduced by non-viral delivery.

### Claim 109 (depends on 77, 78, 79, 80, 81, 82, 83, 84, 85, 89, 90, 91)

The method of any of claims 77-85, 89-91, or 97-108, wherein the nucleic acid encoding the immunomodulator is introduced to the g-NK cell via a lipid nanoparticle.

### Claim 110 (depends on 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109)

The method of any of claims 77-109, wherein the nucleic acid encoding the immunomodulator is DNA.

### Claim 111 (depends on 77, 78, 79, 80, 81, 82, 83, 84, 85, 89, 90, 91)

The method of any of claims 77-85, 89-91, or 97-109, wherein the nucleic acid encoding the immunomodulator is RNA.

### Claim 112 (depends on 111)

The method of claim 111, wherein the RNA is mRNA.

### Claim 113 (depends on 112)

The method of claim 112, wherein the RNA is a self-amplifying mRNA.

### Claim 114 (depends on 77, 78, 79, 80, 81, 82, 83, 84, 85, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103)

The method of any of claims 77-85, 89-103, or 107-113, wherein the nucleic acid encoding the immunomodulator is introduced to the g-NK cell via electroporation.

### Claim 115 (depends on 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114)

The method of any of claims 78-114, wherein the nucleic acid encoding the CAR and the nucleic acid encoding the immunomodulator are encoded from the same polynucleotide and introduced together.

### Claim 116 (depends on 115)

The method of claim 115, wherein the nucleic acid encoding the CAR and the nucleic acid encoding the immunomodulator are separated by a multicistronic element of the polynucleotide sequence.

### Claim 117 (depends on 116)

The method of claim 116, wherein the multicistronic element is a self-cleaving peptide selected from the group consisting of T2A, P2A and F2A.

### Claim 118 (depends on 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114)

The method of any of claims 78-114, wherein the nucleic acid encoding the CAR and the nucleic acid encoding the immunomodulator are introduced simultaneously during an ex vivo process for expanding a population enriched in g-NK cells.

### Claim 119 (depends on 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118)

The method of any of claims 76-118, wherein the g-NK cell composition has been produced by ex vivo expansion of NK cells enriched from a biological sample from a subject that are either (i) negative or low for CD3 and positive for CD57 (CD3negCD57pos) or (ii) negative or low for CD3 and positive for CD56 (CD3negCD56pos), wherein the enriched NK cells are cultured with irradiated HLA-E+ feeder cells and one or more recombinant cytokines. 76. The method of claim 75, wherein the one or more recombinant cytokine is selected from an effective amount of SCF, GSK3i, FLT3, IL-2, IL-6, IL-7, IL-15, IL-12, IL-18, IL-21, IL-27, or combinations thereof.

### Claim 120 (depends on 119)

The method of claim 119, wherein the one or more recombinant cytokine comprises IL-21.

### Claim 121 (depends on 119, 120)

The method of claim 119 or claim 120, wherein the culturing is performed in the presence of two or more recombinant cytokines, wherein at least one recombinant cytokine is interleukin (IL)-2 and at least one recombinant cytokine is IL-21.

### Claim 122 (depends on 76, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96)

The method of any of claims 76, 79-96, or 119-121, wherein the introducing is carried out during a method for expanding FcRγ-deficient NK (g-NK) cells, said method comprising:
(A) obtaining a population of primary human cells enriched for natural killer (NK) cells, wherein the population enriched for NK cells is selected from a biological sample from a human subject; and
(B) culturing the population of engineered NK cells in culture medium with (1) irradiated HLA-E+ feeder cells, wherein the feeder cells are deficient in HLA class I and HLA class II and wherein the ratio of irradiated HLA-E+ feeder cells to enriched NK cells is from 1:10 to 10:1; and (2) an effective amount of two or more recombinant cytokines for expansion of the NK cells, wherein at least one recombinant cytokine is interleukin (IL)-2 and at least one recombinant cytokine is IL-21;
wherein the introducing the nucleic acid encoding the CAR is performed after step (A) and prior to, during or after step (B), thereby producing a population of engineered NK cells; and
wherein the method produces an expanded population of engineered NK cells that are enriched in g-NK cells and comprise cells engineered with a CAR.

### Claim 123 (depends on 76, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96)

The method of any of claims 76, 79-96, or 119-121, wherein the introducing is carried out during a method for expanding FcRγ-deficient NK cells (g-NK), said method comprising:
(A) obtaining a population of primary human cells enriched for natural killer (NK) cells, wherein the population enriched for NK cells is selected from a biological sample from a human subject;
(B) introducing into the population of enriched NK cells the nucleic acid encoding a CAR, thereby producing a population of engineered NK cells; and
(C) culturing the population of engineered NK cells in culture medium with (1) irradiated HLA-E+ feeder cells, wherein the feeder cells are deficient in HLA class I and HLA class II and wherein the ratio of irradiated HLA-E+ feeder cells to enriched NK cells is from 1:10 to 10:1; and (2) an effective amount of two or more recombinant cytokines for expansion of the NK cells, wherein at least one recombinant cytokine is interleukin (IL)-2 and at least one recombinant cytokine is IL-21, thereby producing an expanded population of NK cells; and
wherein the method produces an expanded population of engineered NK cells that are enriched in g-NK cells and comprise cells engineered with a CAR.

### Claim 124 (depends on 76, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96)

The method of any of claims 76, 79-96, or 119-121, wherein the introducing is carried out during a method for expanding FcRγ-deficient NK cells (g-NK), said method comprising:
(A) obtaining a population of primary human cells enriched for natural killer (NK) cells, wherein the population enriched for NK cells is selected from a biological sample from a human subject; and
(B) culturing the population of enriched NK cells in culture medium with (1) irradiated HLA-E+ feeder cells, wherein the feeder cells are deficient in HLA class I and HLA class II and wherein the ratio of irradiated HLA-E+ feeder cells to enriched NK cells is from 1:10 to 10:1; and (2) an effective amount of two or more recombinant cytokines for expansion of the NK cells, wherein at least one recombinant cytokine is interleukin (IL)-2 and at least one recombinant cytokine is IL-21, thereby producing an expanded population of NK cells; and
(C) introducing into NK cells of the expanded population of NK cells the nucleic acid encoding a CAR,
wherein the method produces an expanded population of engineered NK cells that are enriched in g-NK cells and comprises cells engineered with a CAR.

### Claim 125 (depends on 76, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96)

The method of any of claims 76, 79-96, or 119-121, wherein the introducing is carried out during a method for expanding FcRγ-deficient NK cells (g-NK), said method comprising:
(A) obtaining a population of primary human cells enriched for natural killer (NK) cells, wherein the population enriched for NK cells is selected from a biological sample from a human subject; and
(B) performing a first expansion comprising culturing the population of enriched NK cells in culture medium under conditions for expanding the NK cells to produce a first expanded population of NK cells;
(C) introducing into NK cells of the first expanded population of NK cells the nucleic acid encoding a CAR, thereby producing a population of engineered NK cells; and
(D) performing a second expansion comprising culturing the population of engineered NK cells under conditions for further expansion of the NK cells,
wherein the first expansion and/or second expansion comprise culturing the population of enriched NK cells in culture medium with (1) irradiated HLA-E+ feeder cells, wherein the feeder cells are deficient in HLA class I and HLA class II and wherein the ratio of irradiated HLA-E+ feeder cells to enriched NK cells is from 1:10 to 10:1; and (2) an effective amount of two or more recombinant cytokines for expansion of the NK cells, wherein at least one recombinant cytokine is interleukin (IL)-2 and at least one recombinant cytokine is IL-21; and
wherein the method produces an expanded population of engineered NK cells that are enriched in g-NK cells and comprise cells engineered with a CAR.

### Claim 126 (depends on 77, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114)

The method of any of claims 77, 97-114, or 119-121, wherein the introducing is carried out during a method for expanding FcRγ-deficient NK (g-NK) cells, said method comprising:
(A) obtaining a population of primary human cells enriched for natural killer (NK) cells, wherein the population enriched for NK cells is selected from a biological sample from a human subject; and
(B) culturing the population of engineered NK cells in culture medium with (1) irradiated HLA-E+ feeder cells, wherein the feeder cells are deficient in HLA class I and HLA class II and wherein the ratio of irradiated HLA-E+ feeder cells to enriched NK cells is from 1:10 to 10:1; and (2) an effective amount of two or more recombinant cytokines for expansion of the NK cells, wherein at least one recombinant cytokine is interleukin (IL)-2 and at least one recombinant cytokine is IL-21;
wherein the introducing the nucleic acid encoding the immunomodulator is performed after step (A) and prior to, during or after step (B), thereby producing a population of engineered NK cells; and
wherein the method produces an expanded population of engineered NK cells that are enriched in g-NK cells and comprises cells engineered with an immunomodulator.

### Claim 127 (depends on 77, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114)

The method of any of claims 77, 97-114, or 119-121, wherein the introducing is carried out during a method for expanding FcRγ-deficient NK cells (g-NK), said method comprising:
(A) obtaining a population of primary human cells enriched for natural killer (NK) cells, wherein the population enriched for NK cells is selected from a biological sample from a human subject;
(B) introducing into the population of enriched NK cells the nucleic acid encoding an immunomodulator, thereby producing a population of engineered NK cells; and
(C) culturing the population of engineered NK cells in culture medium with (1) irradiated HLA-E+ feeder cells, wherein the feeder cells are deficient in HLA class I and HLA class II and wherein the ratio of irradiated HLA-E+ feeder cells to enriched NK cells is from 1:10 to 10:1; and (2) an effective amount of two or more recombinant cytokines for expansion of the NK cells, wherein at least one recombinant cytokine is interleukin (IL)-2 and at least one recombinant cytokine is IL-21, thereby producing an expanded population of NK cells; and
wherein the method produces an expanded population of engineered NK cells that are enriched in g-NK cells and comprise cells engineered with an immunomodulator.

### Claim 128 (depends on 77, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114)

The method of any of claims 77, 97-114, or 119-121, wherein the introducing is carried out during a method for expanding FcRγ-deficient NK cells (g-NK), said method comprising:
(A) obtaining a population of primary human cells enriched for natural killer (NK) cells, wherein the population enriched for NK cells is selected from a biological sample from a human subject; and
(B) culturing the population of enriched NK cells in culture medium with (1) irradiated HLA-E+ feeder cells, wherein the feeder cells are deficient in HLA class I and HLA class II and wherein the ratio of irradiated HLA-E+ feeder cells to enriched NK cells is from 1:10 to 10:1; and (2) an effective amount of two or more recombinant cytokines for expansion of the NK cells, wherein at least one recombinant cytokine is interleukin (IL)-2 and at least one recombinant cytokine is IL-21, thereby producing an expanded population of NK cells; and
(C) introducing into NK cells of the expanded population of NK cells the nucleic acid encoding an immunomodulator,
wherein the method produces an expanded population of engineered NK cells that are enriched in g-NK cells and comprise cells engineered with an immunomodulator.

### Claim 129 (depends on 77, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114)

The method of any of claims 77, 97-114, or 119-121, wherein the introducing is carried out during a method for expanding FcRγ-deficient NK cells (g-NK), said method comprising:
(A) obtaining a population of primary human cells enriched for natural killer (NK) cells, wherein the population enriched for NK cells is selected from a biological sample from a human subject; and
(B) performing a first expansion comprising culturing the population of enriched NK cells in culture medium under conditions for expanding the NK cells to produce a first expanded population of NK cells;
(C) introducing into NK cells of the first expanded population of NK cells (the nucleic acid encoding an immunomodulator, thereby producing a population of engineered NK cells; and
(D) performing a second expansion comprising culturing the population of engineered NK cells under conditions for further expansion of the NK cells,
wherein the first expansion and/or second expansion comprise culturing the population of enriched NK cells in culture medium with (1) irradiated HLA-E+ feeder cells, wherein the feeder cells are deficient in HLA class I and HLA class II and wherein the ratio of irradiated HLA-E+ feeder cells to enriched NK cells is from 1:10 to 10:1; and (2) an effective amount of two or more recombinant cytokines for expansion of the NK cells, wherein at least one recombinant cytokine is interleukin (IL)-2 and at least one recombinant cytokine is IL-21; and
wherein the method produces an expanded population of engineered NK cells that are enriched in g-NK cells and comprise cells engineered with an immunomodulator.

### Claim 130 (depends on 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121)

The method of any of claims 78-121, wherein the introducing is carried out during a method for expanding FcRγ-deficient NK (g-NK) cells, said method comprising:
(A) obtaining a population of primary human cells enriched for natural killer (NK) cells, wherein the population enriched for NK cells is selected from a biological sample from a human subject; and
(B) culturing the population of engineered NK cells in culture medium with (1) irradiated HLA-E+ feeder cells, wherein the feeder cells are deficient in HLA class I and HLA class II and wherein the ratio of irradiated HLA-E+ feeder cells to enriched NK cells is from 1:10 to 10:1; and (2) an effective amount of two or more recombinant cytokines for expansion of the NK cells, wherein at least one recombinant cytokine is interleukin (IL)-2 and at least one recombinant cytokine is IL-21;
wherein the introducing (i) the nucleic acid encoding the CAR and/or (ii) the nucleic acid encoding the immunomodulator is performed after step (A) and prior to, during or after step (B), wherein steps (i) and (ii) are carried out simultaneously or sequentially in any order, thereby producing a population of engineered NK cells; and
wherein the method produces an expanded population of engineered NK cells that are enriched in g-NK cells and comprise cells engineered with a CAR and an immunomodulator.

### Claim 131 (depends on 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121)

The method of any of claims 78-121, wherein the introducing is carried out during a method for expanding FcRγ-deficient NK cells (g-NK), said method comprising:
(A) obtaining a population of primary human cells enriched for natural killer (NK) cells, wherein the population enriched for NK cells is selected from a biological sample from a human subject;
(B) introducing into the population of enriched NK cells (i) the nucleic acid encoding a CAR, and (ii) the nucleic acid encoding an immunomodulator, wherein steps (i) and (ii) are carried out simultaneously or sequentially in any order, thereby producing a population of engineered NK cells; and
(C) culturing the population of engineered NK cells in culture medium with (1) irradiated HLA-E+ feeder cells, wherein the feeder cells are deficient in HLA class I and HLA class II and wherein the ratio of irradiated HLA-E+ feeder cells to enriched NK cells is from 1:10 to 10:1; and (2) an effective amount of two or more recombinant cytokines for expansion of the NK cells, wherein at least one recombinant cytokine is interleukin (IL)-2 and at least one recombinant cytokine is IL-21, thereby producing an expanded population of NK cells; and
wherein the method produces an expanded population of engineered NK cells that are enriched in g-NK cells and comprise cells engineered with a CAR and an immunomodulator.

### Claim 132 (depends on 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121)

The method of any of claims 78-121, wherein the introducing is carried out during a method for expanding FcRγ-deficient NK cells (g-NK), said method comprising:
(A) obtaining a population of primary human cells enriched for natural killer (NK) cells, wherein the population enriched for NK cells is selected from a biological sample from a human subject; and
(B) culturing the population of enriched NK cells in culture medium with (1) irradiated HLA-E+ feeder cells, wherein the feeder cells are deficient in HLA class I and HLA class II and wherein the ratio of irradiated HLA-E+ feeder cells to enriched NK cells is from 1:10 to 10:1; and (2) an effective amount of two or more recombinant cytokines for expansion of the NK cells, wherein at least one recombinant cytokine is interleukin (IL)-2 and at least one recombinant cytokine is IL-21, thereby producing an expanded population of NK cells; and
(C) introducing into NK cells of the expanded population of NK cells (i) the nucleic acid encoding a CAR, and (ii) the nucleic acid encoding an immunomodulator, wherein steps (i) and (ii) are carried out simultaneously or sequentially in any order,
wherein the method produces an expanded population of engineered NK cells that are enriched in g-NK cells and comprise cells engineered with a CAR and an immunomodulator.

### Claim 133 (depends on 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121)

The method of any of claims 78-121, wherein the introducing is carried out during a method for expanding FcRγ-deficient NK cells (g-NK), said method comprising:
(A) obtaining a population of primary human cells enriched for natural killer (NK) cells, wherein the population enriched for NK cells is selected from a biological sample from a human subject; and
(B) performing a first expansion comprising culturing the population of enriched NK cells in culture medium under conditions for expanding the NK cells to produce a first expanded population of NK cells;
(C) introducing into NK cells of the first expanded population of NK cells (i) the nucleic acid encoding a CAR, and (ii) the nucleic acid encoding an immunomodulator, wherein steps (i) and (ii) are carried out simultaneously or sequentially in any order, thereby producing a population of engineered NK cells; and
(D) performing a second expansion comprising culturing the population of engineered NK cells under conditions for further expansion of the NK cells,
wherein the first expansion and/or second expansion comprise culturing the population of enriched NK cells in culture medium with (1) irradiated HLA-E+ feeder cells, wherein the feeder cells are deficient in HLA class I and HLA class II and wherein the ratio of irradiated HLA-E+ feeder cells to enriched NK cells is from 1:10 to 10:1; and (2) an effective amount of two or more recombinant cytokines for expansion of the NK cells, wherein at least one recombinant cytokine is interleukin (IL)-2 and at least one recombinant cytokine is IL-21; and
wherein the method produces an expanded population of engineered NK cells that are enriched in g-NK cells and comprise cells engineered with a CAR and an immunomodulator.

### Claim 134 (depends on 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133)

The method of any of claims 119-133, wherein the population of primary human cells enriched for NK cells are obtained by selecting from a biological sample from a human subject cells that are either (i) negative or low for CD3 and positive for CD57 (CD3negCD57pos) or (ii) negative or low for CD3 and positive for CD56 (CD3negCD56pos).

### Claim 135 (depends on 134)

The method of claim 134, wherein:
the population enriched for NK cells are cells further selected for cells positive for NKG2C (NKG2Cpos);
the population enriched for NK cells are cells further selected for cells negative or low for NKG2A (NKG2Aneg); or
the population enriched for NK cells are cells further selected for cells positive for NKG2C and negative or low for NKG2A (NKG2CposNKG2Aneg).

### Claim 136 (depends on 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135)

The method of any of claims 119-135, wherein the human subject is a subject in which at least at or about 20% of natural killer (NK) cells in a peripheral blood sample from the subject are positive for NKG2C (NKG2Cpos) and at least 70% of NK cells in the peripheral blood sample are negative or low for NKG2A (NKG2Aneg).

### Claim 137 (depends on 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136)

The method of any of claims 119-136, wherein the subject is CMV-seropositive.

### Claim 138 (depends on 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137)

The method of any of claims 119-137, wherein the percentage of g-NK cells among NK cells in the biological sample from the subject is greater than at or about 5%, greater than at or about 10% or greater than at or about 30%.

### Claim 139 (depends on 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138)

The method of any of claims 119-138, wherein the percentage of g-NK cells among the population of enriched NK cells is between at or about 20% and at or about 90%, is between at or about 40% and at or about 90% or is between at or about 60% and at or about 90%.

### Claim 140 (depends on 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139)

The method of any of claims 119-139, wherein the population enriched for NK cells are cells selected from the biological sample that are negative or low for CD3 and positive for CD57 (CD3negCD57pos).

### Claim 141 (depends on 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140)

The method of any of claims 119-140, wherein the population enriched for NK cells are cells selected from the biological sample that are negative or low for CD3 and positive for CD56 (CD3negCD56pos).

### Claim 142 (depends on 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141)

The method of any of claims 119-141, wherein the two or more recombinant cytokines further comprises an effective amount of SCF, GSK3i, FLT3, IL-6, IL-7, IL-15, IL-12, IL-18, IL-27, or combinations thereof.

### Claim 143 (depends on 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142)

The method of any of claims 114-142, wherein the recombinant cytokines are IL-21 and IL-2.

### Claim 144 (depends on 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142)

The method of any of claims 114-142, wherein the recombinant cytokines are IL-21, IL-2, and IL-15.

### Claim 145 (depends on 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144)

The method of any of claims 114-144, wherein recombinant IL-21 is added to the culture medium during at least a portion of the culturing at a concentration that is from at or about 10 ng/mL to at or about 100 ng/mL.

### Claim 146 (depends on 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145)

The method of any of claims 114-145, wherein recombinant IL-21 is added to the culture medium during at least a portion of the culturing at a concentration that is at or about 25 ng/mL.

### Claim 147 (depends on 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146)

The method of any of claims 114-146, wherein recombinant IL-2 is added to the culture medium during at least a portion of the culturing at a concentration that is from at or about 10 IU/mL to at or about 500 IU/mL.

### Claim 148 (depends on 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147)

The method of any of claims 114-147, wherein recombinant IL-2 is added to the culture medium during at least a portion of the culturing at a concentration that is at or about 100 IU/mL.

### Claim 149 (depends on 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148)

The method of any of claims 114-148, wherein recombinant IL-2 is added to the culture medium during at least a portion of the culturing at a concentration that is at or about 500 IU/mL.

### Claim 150 (depends on 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 144, 145, 146, 147, 148, 149)

The method of any of claims 114-142 and 144-149, wherein recombinant IL-15 is added to the culture medium during at least a portion of the culturing at a concentration that is from at or about 1 ng/mL to 50 ng/mL.

### Claim 151 (depends on 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 144, 145, 146, 147, 148)

The method of any of claims 114-142 and 144-148, wherein recombinant IL-15 is added to the culture medium during at least a portion of the culturing at a concentration that is at or about 10 ng/mL.

### Claim 152 (depends on 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151)

The method of any of claims 114-151, wherein the recombinant cytokines are added to the culture medium beginning at or about the initiation of the culturing.

### Claim 153 (depends on 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152)

The method of any of claims 114-152, wherein the method further comprises exchanging the culture medium one or more times during the culturing, wherein at each exchange of the culture medium, fresh media containing the recombinant cytokines is added.

### Claim 154 (depends on 153)

The method of claim 153, wherein the exchanging of the culture medium is carried out every two or three days for the duration of the culturing.

### Claim 155 (depends on 153, 154)

The method of claim 153 or claim 154, wherein exchanging the media is performed after a first expansion without media exchange for up to 5 days, optionally after a first expansion without media exchange for up to 5 days.

### Claim 156 (depends on 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155)

The method of any of claims 114-155, wherein the human subject has the CD16 158V/V NK cell genotype or the CD16 158V/F NK cell genotype, optionally wherein the biological sample is from a human subject selected for the CD16 158V/V NK cell genotype or the CD16 158V/F NK cell genotype.

### Claim 157 (depends on 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156)

The method of any of claims 114-156, wherein the biological sample is or comprises peripheral blood mononuclear cells (PBMCs), optionally is a blood sample, an apheresis sample or a leukapheresis sample.

### Claim 158 (depends on 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157)

The method of any of claims 114-157, wherein the HLA-E+ feeder cells are K562 cells transformed with HLA-E (K562-HLA-E).

### Claim 159 (depends on 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158)

The method of any of claims 114-158, wherein the HLA-E+ feeder cells are 221.AEH cells.

### Claim 160 (depends on 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159)

The method of any of claims 114-159, wherein the ratio of irradiated HLA-E+ feeder cells to enriched NK cells is between 1:1 and 5:1, inclusive is between 1:1 and 3:1, inclusive, optionally is or is about 2.5:1 or is or is about 2:1 or is about 1:1

### Claim 161 (depends on 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160)

The method of any of claims 114-160, wherein the recombinant cytokines added to the culture medium during at least a portion of the culturing are 500 IU/mL IL-2, 10 ng/mL IL-15, and 25 ng/mL IL-21.

### Claim 162 (depends on 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161)

The method of any of claims 114-161, wherein the population of enriched NK cells comprises between at or about 2.0×105 enriched NK cells and at or about 5.0×107 enriched NK cells, between at or about 1.0×106 enriched NK cells and at or about 1.0×108 enriched NK cells, between at or about 1.0×107 enriched NK cells and at or about 5.0×108 enriched NK cells, or between at or about 1.0×107 enriched NK cells and at or about 1.0×108 enriched NK cells, each inclusive, optionally wherein the population of enriched NK cells comprises at or about 1.0×106 enriched NK cells.

### Claim 163 (depends on 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162)

The method of any of claims 114-162, wherein the population of enriched NK cells at the initiation of the culturing is at a concentration of between or between about 0.05×106 enriched NK cells/mL and 1.0×106 enriched NK cells/mL or between or between about 0.05×106 enriched NK cells/mL and 0.5×106 enriched NK cells/mL, optionally wherein the population of enriched NK cells at the initiation of the culturing comprises a concentration of or about 0.2×106 enriched NK cells/mL.

### Claim 164 (depends on 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163)

The method of any of claims 114-163, wherein the culturing is carried out until a time at which the method achieves expansion of at least or at least about 2.50×108 g-NK cells, at least or at least about 5.00×108 g-NK cells, at least or at least about 1.0×109 g-NK cells or at least or at least about 5.0×109 g-NK cells.

### Claim 165 (depends on 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164)

The method of any of claims 114-164, wherein the culturing is carried out for or about or at least or at least about 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 15 days, 16 days, 17 days, 18 days, 19 days, 20 day, 21 days, 22 days, 23 days, 24 days or 25 days.

### Claim 166 (depends on 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165)

The method of any of claims 114-165 further comprising collecting the expanded population of engineered NK cells produced by the method.

### Claim 167 (depends on 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166)

The method of any of claims 114-166, further comprising formulating the expanded population of engineered NK cells in a pharmaceutically acceptable excipient.

### Claim 168 (depends on 167)

The method of claim 167, further comprising formulating the expanded population of engineered NK cells with a serum-free cryopreservation medium comprising a cryoprotectant.

### Claim 169 (depends on 168)

The method of claim 168, wherein the cryoprotectant is DMSO, optionally wherein the cryoprotectant is DMSO and the cryopreservation medium is 5% to 10% DMSO (v/v), optionally is or is about 10% DMSO (v/v).

### Claim 170 (depends on 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169)

The method of any of claims 114-169, wherein, among the expanded population of engineered NK cells produced by the method, greater than 50% of the population are FcRγneg, greater than 60% of the population are FcRγneg, greater than 70% of the population are FcRγneg, greater than 80% of the population are FcRγneg, greater than 90% of the population are FcRγneg or greater than 95% of the population are FcRγneg.

### Claim 171 (depends on 76, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 119, 120, 121, 122, 123, 124, 125)

A composition comprising a plurality of engineered NK cells produced by the method of any one of claims 76, 78-96, 119-125, or 134-170-.

### Claim 172 (depends on 77, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 119, 120, 121, 126, 127, 128, 129)

A composition comprising a plurality of engineered NK cells produced by the method of any one of claims 77, 97-114, 119-121, 126-129, or 134-170.

### Claim 173 (depends on 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170)

A composition comprising a plurality of engineered NK cells produced by the method of any one of claims 77-121 or 130-170.

### Claim 174 (depends on 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 171, 172, 173)

A method of treating a disease or condition in a subject, comprising administering an effective amount of cells of the composition of any of claims 29-73 or 171-173 to an individual in need thereof.

### Claim 175 (depends on 174)

The method of claim 174, wherein the disease or condition is selected from the group consisting of an inflammatory condition, an infection, or cancer.

### Claim 176 (depends on 174, 175)

The method of claim 174 or claim 175, wherein the disease or condition is a cancer and the cancer is leukemia, a lymphoma, or a myeloma.

### Claim 177 (depends on 174, 175)

The method of claim 174 or claim 175, wherein the disease or condition is a cancer and the cancer comprises a solid tumor.

### Claim 178 (depends on 177)

The method of claim 177, wherein the cancer is selected from among an adenocarcinoma of the stomach or gastroesophageal junction, a bladder cancer, a breast cancer, a brain cancer, a cervical cancer, a colorectal cancer, an endocrine/neuroendocrine cancer, a head and neck cancer, a gastrointestinal stromal cancer, a giant cell tumor of the bone, a kidney cancer, a liver cancer, a lung cancer, a neuroblastoma, an ovarian epithelial/fallopian tube/primary peritoneal cancers, a pancreatic cancer, a prostate cancer, a skin cancer, and a soft tissue carcinoma.

### Claim 179 (depends on 174, 175, 176, 177, 178)

The method of any of claims 174-178, wherein the composition is administered as a monotherapy.

### Claim 180 (depends on 174, 175, 176, 177, 178, 179)

The method of any of claims 174-179, further comprising administering an additional agent to the individual for treating the disease or condition.

### Claim 181 (depends on 180)

The method of claim 180, wherein the additional agent is an antibody or an Fc-fusion protein.

### Claim 182 (depends on 180, 181)

The method of claim 180 or claim 181, wherein the additional agent is an antibody that is a monoclonal antibody.

### Claim 183 (depends on 181, 182)

The method of claim 181 or claim 182, wherein the antibody is a full-length antibody.

### Claim 184 (depends on 181, 182, 183)

The method of any of claims 181-183, wherein the antibody is an IgG1 antibody.

### Claim 185 (depends on 180, 181, 182, 183, 184)

The method of claim 180-184, wherein the disease or condition is a cancer and the additional agent, optionally the antibody, recognizes a tumor antigen associated with the cancer.

### Claim 186 (depends on 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185)

The method of any of claims 174-185, comprising administering from at or about 1×105 to at or about 50×109 cells of the g-NK cell composition to the individual.

### Claim 187 (depends on 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186)

The method of any of claims 174-186, comprising administering from at or about from at or about 1×108 cells to at or about 50×109 NK cells of the g-NK cell composition, optionally at or about 5×108 cells of the g-NK cell composition, at or about 5×109 cells of the g-NK cell composition or at or about 10×109 cells of the g-NK cell composition.

### Claim 188 (depends on 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187)

The method of any one of claims 174-187, further comprising administering exogenous cytokine support to facilitate expansion or persistence of the administered NK cells in vivo in the subject, optionally wherein the exogenous cytokine is or comprises IL-15.

### Claim 189 (depends on 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188)

The method of any of claims 174-188, wherein prior to the administration of the dose of g-NK cells, the subject has received a lymphodepleting therapy.

### Claim 190 (depends on 129)

The method of claim 129, wherein the lymphodepleting therapy comprises fludarabine and/or cyclophosphamide.

### Claim 191 (depends on 189, 190)

The method of claim 189 or claim 190, wherein the lymphodepleting comprises the administration of fludarabine at or about 20-40 mg/m2 body surface area of the subject, optionally at or about 30 mg/m2, daily, for 2-4 days, and/or cyclophosphamide at or about 200-400 mg/m2 body surface area of the subject, optionally at or about 300 mg/m2, daily, for 2-4 days.

### Claim 192 (depends on 189, 190, 191)

The method of any of claims 189-191, wherein the lymphodepleting therapy comprises fludarabine and cyclophosphamide.

### Claim 193 (depends on 189, 190, 191, 192)

The method of any of claims 189-192, wherein the lymphodepleting therapy comprises the administration of fludarabine at or about 30 mg/m2 body surface area of the subject, daily, and cyclophosphamide at or about 300 mg/m2 body surface area of the subject, daily, each for 2-4 days, optionally 3 days.

### Claim 194 (depends on 189, 190, 191, 192, 193)

The method of any of claims 189-193, wherein administration of the cells is initiated within two weeks or at or about two weeks after initiation of the lymphodepleting therapy.

### Claim 195 (depends on 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194)

The method of any one of claims 174-194, wherein the individual is a human.

### Claim 196 (depends on 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195)

The method of any one of claims 174-195, wherein the NK cells in the composition are allogenic to the individual.

### Claim 197 (depends on 189, 190, 191, 192, 193, 194, 195)

The method of any one of claims 189-195, wherein the NK cells in the composition are autologous to the subject.
